MedTrace Logo

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

NCT03118180 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-04-18

No results posted yet for this study

Summary

A prospective study to evaluate the safety and efficacy of CART19 for refractory/relapsed B cell lymphoma.

Conditions

Interventions

BIOLOGICAL

CD19 targeted chimeric antigen receptor T cells

CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma

Sponsors & Collaborators

  • Innovative Cellular Therapeutics Co., Ltd.

    collaborator OTHER

  • Zhejiang University

    lead OTHER

Principal Investigators

  • He Huang, Dr · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-05
Primary Completion
2018-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03118180 on ClinicalTrials.gov